Skeletal muscle is the principal tissue responsible for insulinstimulated glucose disposal and is a major site of peripheral insulin resistance. Urocortin 2 (Ucn 2), a member of the corticotropinreleasing factor (CRF) family, and its cognate type 2 CRF receptor (CRFR2) are highly expressed in skeletal muscle. To determine the physiological role of Ucn 2, we generated mice that are deficient in this peptide. Using glucose-tolerance tests (GTTs), insulin-tolerance tests (ITTs), and hyperinsulinemic euglycemic glucose clamp studies, we demonstrated that mice lacking Ucn 2 exhibited increased insulin sensitivity and were protected against fat-induced insulin resistance. Administration of synthetic Ucn 2 to mutant mice before the GTTs and ITTs restored blood glucose to WT levels. Administration of a CRFR2 selective antagonist to WT mice resulted in a GTT profile that mirrored that of Ucn 2-null mice. Body composition measurements of Ucn 2-null mice on a high-fat diet demonstrated decreases in fat and increases in lean tissue compared with WT mice. We propose that null mutant mice display increased glucose uptake in skeletal muscle through the removal of Ucn 2-mediated inhibition of insulin signaling. In keeping with these data, Ucn 2 inhibited insulin-induced Akt and ERK1͞2 phosphorylation in cultured skeletal muscle cells and C2C12 myotubes. These data are consistent with the hypothesis that Ucn 2 functions as a local negative regulator of glucose uptake in skeletal muscle and encourage exploration of the possibility that suppression of the Ucn 2͞CRFR2 pathway may provide benefits in insulin-resistant states such as type 2 diabetes.
corticotropin-releasing factor ͉ type 2 diabetes ͉ urocortin 2 knockout ͉ glucose homeostasis I nsulin resistance is a characteristic feature in the pathogenesis of type 2 diabetes and obesity (1) (2) (3) (4) . Although the molecular mechanisms causing this disease are not fully understood, impaired whole-body glucose uptake due to insulin resistance plays a significant role (5) (6) (7) . Skeletal muscle constitutes the largest insulin-sensitive tissue in humans, and, thus, insulin resistance in this organ impacts whole-body glucose homeostasis (8, 9) . Although major advances have been made in our understanding of the molecular mechanisms of insulin action in muscle, little is known of local muscle factors that can modulate insulin action and glucose transport. The neuropeptide corticotropin-releasing factor (CRF) is a key regulator of the hypothalamic-pituitaryadrenal axis under basal and stress conditions (10, 11) and integrates endocrine, autonomic, and behavioral responses to stressors (12) (13) (14) . It has been suggested that the CRF family peptides and their cognate receptors play a role in modulating energy homeostasis (15) (16) (17) (18) . Urocortin 2 (Ucn 2, also known as stresscopin-related peptide), a recently identified member of the CRF family (19) (20) (21) , and its high-affinity, membrane-bound type 2 CRF receptor (CRFR2) (22) (23) (24) (25) are highly expressed in skeletal muscle (21) (22) (23) ; however, the physiological functions of Ucn 2 and CRFR2 in this tissue are not known.
Results and Discussion
Generation of Ucn 2-Deficient Mice. To explore the physiological role of Ucn 2, we generated mice that are deficient in this peptide. A genomic DNA clone containing Ucn 2 was isolated, and a targeting construct in which the full Ucn 2 coding sequence was replaced with a neomycin-resistant gene cassette was generated ( Fig. 1a) . J1 ES cells were electroporated with the targeting construct and were selected as described in ref. 26 . Targeted ES cells were injected into C57BL͞6 mice blastocysts to generate chimeric mice, which transmitted the null mutation through the germ line. Germ-line transmission of the disrupted allele was confirmed by Southern blot analysis by using a 3Ј probe (probe A) or 5Ј probe (probe B) (Fig. 1b) . We carried out RT-PCR, RIA, and immunohistochemical staining and determined that Ucn 2 mRNA (Fig. 1c) and peptide ( Fig. 1 d and e) were not detected in Ucn 2 mutant mice, demonstrating that disruption of Ucn 2 resulted in a null mutation. Mutant mice are fertile, and the mutant allele was transmitted in a Mendelian fashion.
Metabolic Phenotype of Ucn 2-Null Mice. The ability of the Ucn 2-null mice and their WT littermates to handle a glucose load was assessed by using a standard glucose-tolerance test (GTT). Glucose tolerance was significantly enhanced in the mutant mice compared with their WT littermates (Fig. 2a) . Administration of synthetic Ucn 2 peptide to mutant mice before the GTT restored blood glucose to WT levels (Fig. 2b) . Accordingly, administration of the CRFR2 selective antagonist astressin 2B (27) to WT mice resulted in a GTT profile that mirrors that of Ucn 2-null mice (Fig. 2c) . Fasting basal and glucose-induced elevated insulin levels were similar in the two groups (Fig. 2d) , suggesting that enhanced glucose tolerance in Ucn 2-null mice is not due to increased insulin secretion into the bloodstream. Ucn 2-null mice demonstrated increased insulin sensitivity compared with their WT littermates as determined by an insulin-tolerance test (ITT) (Fig. 2e) . Administration of synthetic Ucn 2 peptide to null mutant mice before the ITT restored blood glucose levels to those of WT mice (Fig. 2f ).
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Dynamic Metabolic Studies of Ucn 2-Null Mice. Because insulin tolerance testing assesses glucose disposal after an acute i.p. injection of insulin, we examined whole-body glucose homeostasis by using hyperinsulinemic euglycemic glucose clamp studies. During constant hyperinsulinemia in mice fed a standard chow diet, higher glucose infusion rates were required to maintain normal glucose levels in Ucn 2-null mice compared with their WT littermates (Fig. 3 a and b) . To evaluate the contribution of peripheral tissues to the increased insulin responsiveness, the actions of insulin on liver, fat, and skeletal muscle were measured by using radiolabeled glucose analogues during the clamp studies ( Fig. 3 c-f ). Whole-body glucose uptake (peripheral insulin sensitivity), glycolysis, and insulin-mediated suppression of hepatic glucose production rates (hepatic insulin sensitivity) were significantly increased in the mutant mice compared with WT littermates (Fig. 3 c and d ). An insulin sensitivity index of adipose tissue, measured as suppression of lipolysis, was increased in mutant mice compared with WT littermates (Fig. 3e) . To assess the effect of the Ucn 2-null mutation on skeletal muscle, we measured specific glucose uptake into the gastrocnemius muscle and found a significant increase of deoxy- [2- 3 H] glucose uptake in skeletal muscle of mutant mice as compared with WT littermates (Fig. 3f ). Data from these clamp studies were congruent with our initial observation that Ucn 2-null mice are more insulin sensitive than WT control mice. Mice fed a high-fat diet provide a well established model for studying impaired glucose tolerance and ontogeny of type 2 diabetes. To explore glucose metabolism in Ucn 2-null mice, mutant and WT mice were placed on a high-fat (45% of calories from fat) or a standard chow (11% of calories from fat) diet for 16 weeks (Fig.  4 a-f ). The weight gain (Fig. 4d) and food consumed on a standard or high-fat diet (Fig. 4c) by the Ucn 2-null mice were similar to those of the WT mice. Remarkably, however, significant increases in blood glucose (Fig. 4a ) and insulin levels ( Fig. 4b) were observed in the WT mice but not in Ucn 2-null mice. Body composition measurements determined by using dual-energy x-ray absorptiometry (28) of Ucn 2-null mice on a high-fat diet demonstrated decreases in fat (Fig. 4e ) and increases in lean tissue (Fig. 4f ) compared with WT littermates. To assess insulin actions on wholebody, liver, and skeletal muscle tissues, we performed hyperinsulinemic euglycemic clamp studies on both WT and Ucn 2-null mice that were fed a high-fat diet (55% of calories from fat) for 3 weeks (Fig. 4 g-j) . Ucn 2-null mice on a high-fat diet required higher glucose infusion rates to maintain normal glucose levels in hyperinsulinemic euglycemic glucose clamp studies (Fig. 4 g and h) . Furthermore, whole-body glucose uptake and glycogen synthesis (Fig. 4i ) and specific glucose uptake by gastrocnemius tissue (Fig.  4j) were significantly increased in mutant mice compared with WT littermates. These data demonstrate that mice lacking Ucn 2 have increased glucose utilization and are protected against fat-induced insulin resistance in skeletal muscle.
Ucn 2 Effects on Muscle Glucose Uptake Are Mediated Putatively by
Inhibition of Insulin Signaling. The insulin signaling pathways controlling glucose transport into skeletal muscle are complex; multiple effector proteins are believed to orchestrate diverse cellular responses (6, 7, 29) . Adding to this complexity, the signaling pathways are not linear, and there is a high degree of cross-talk between the signal transducers. The serine͞threonine kinase Akt͞PKB plays a key role in insulin signaling, and its activation by insulin has been shown to play a crucial role in the control of GLUT4 (glucose transporter 4) translocation and glycogen metabolism (6, 7, 29) . To establish that Ucn 2 can have direct effects on skeletal muscle, we studied the effects of Ucn 2 on insulin signaling in cultured skeletal muscle cells and C2C12 myotubes. Ucn 2 inhibits insulin-induced phosphorylation of Akt in C2C12 myotubes (Fig. 5 a and b) and in cultured skeletal muscle cells (Fig. 5 c and d) . The inhibitory effect of Ucn 2 and CRFR2 activation on insulin receptor signaling may be mediated early in the signaling cascade, because ERK1͞2 phosphorylation after insulin stimulation is also inhibited by Ucn 2 treatment (Fig. 5 e and f ) . The ␤-adrenergic agonist isoproterenol was also previously demonstrated to markedly reduce the increase in ERK1͞2 activities produced by insulin in rat adipocytes (30) . Ucn 2 inhibits insulin-induced glucose uptake in C2C12 myotubes (Fig.  5g) . This dose-dependent inhibition is consistent with the inhibition of insulin signaling by Ucn 2. These results suggest that Ucn 2 inhibits interactions between the insulin signaling pathway components. The molecular mechanism by which Ucn 2, acting through its specific G protein-coupled receptor, inhibits insulin receptor signaling remains to be determined. Skeletal muscle accounts for Ϸ80% of glucose disposal after glucose infusion and is of principal importance in maintaining glucose homeostasis (29, 31) . Alterations in signal transduction to glucose transport have a profound effect on whole-body glucose homeostasis (5-9). Ucn 2 and its specific receptor, CRFR2, are highly expressed by skeletal muscle and can serve as an autocrine and͞or paracrine regulator of glucose uptake in this tissue. Although the primary defects that are responsible for the development of type 2 diabetes are unclear, insulin resistance in skeletal muscle is a hallmark of the disease (5-9). In normal glucosetolerant relatives of type 2 diabetic patients, insulin resistance in skeletal muscle has been observed several years before the development of overt diabetes (32, 33) . Thus, impaired insulin action in skeletal muscle may constitute an early defect in the pathogenesis of type 2 diabetes. Maintaining glucose homeostasis in the presence of diverse challenges, such as starvation, requires numerous adaptive responses. We have shown that Ucn 2 can regulate glucose utilization by modulating insulin sensitivity in skeletal muscle. Ucn 2, by decreasing glucose uptake in skeletal muscle, may serve an important adaptive function to increase glucose availability for other tissues under specific conditions. Generation of muscle-or brain-specific Ucn 2 knockout mice would facilitate our understanding of the role of central Ucn 2 to the observed phenotype. Our data support a physiological function for Ucn 2 peptide as a local regulator of glucose uptake in muscle and suggest a potential therapeutic use for antagonists of its cognate receptor in the management of type 2 diabetes.
Materials and Methods Construction of Ucn 2-Null Mice.
A genomic DNA clone containing the Ucn 2 gene locus was isolated, and a targeting construct in which Fig. 4 . Ucn 2-null mice placed on a high-fat diet exhibit increased insulin sensitivity and are protected against fat-induced insulin resistance. (a-f ) Ucn 2-null mice and their WT littermates were placed on a high-fat diet (45% of calories from fat) or standard chow diet (10% of calories from fat) for 16 weeks. Significant increases in blood glucose (a) and insulin (b) levels were observed in the WT mice but not in Ucn 2-null mice. No differences were observed in food intake (c) or body weight (d) when comparing mutant and WT mice in the high-fat and low-fat groups. Body composition of Ucn 2-null mice on a high-fat diet shows decreases in fat (e) and increases in lean tissue ( f) compared with WT littermates. (g-j) Hyperinsulinemic euglycemic clamp studies of Ucn 2-null mice and their WT littermates maintained on a high-fat diet (55% of calories from fat) for 3 weeks. (g) The glucose infusion rate (GINF) required to maintained euglycemia in mutant mice was significantly higher than that of WT littermates. (h) Blood glucose levels during the clamp study were maintained at the level of Ϸ120 mg͞dl. (i and j) Whole-body glucose uptake (peripheral insulin sensitivity, i) and specific glucose uptake by the gastrocnemius muscle tissue (j) are significantly increased in Ucn 2-null mice compared with WT littermates.
the Ucn 2 coding sequence was replaced with a neomycin-resistant gene cassette was generated. ES cell cultures were established, and positive ES clones were injected into C57BL͞6 blastocysts to generate chimeric mice as described in ref. 26 . Chimeras were mated to produce heterozygous mutant mice on a mixed C57BL͞6 and 129 genetic background. Breeding of these mice was continued and maintained by means of heterozygote ϫ heterozygote nonsibling matings. Mutant mice were fertile, and the mutant allele was transmitted in a Mendelian fashion. All animal protocols were approved by the Salk Institute for Biological Studies Institutional Animal Care and Use Committee. Detailed descriptions of the RNA preparation and semiquantitative RT-PCR, immunohistochemistry, and RIA used to demonstrate the null mutation can be found in the Supporting Materials and Methods, which is published as supporting information on the PNAS web site.
GTT, ITT, and Insulin-Release Assay. For the GTT, glucose (2 g͞kg of body weight) was injected i.p. after mice were fasted overnight for 14 h. Whole venous blood obtained from the tail vein at 0, 15, 30, 60, 90, and 120 min after the injection was measured for glucose by using an automatic glucometer (One Touch, Lifescan, Daly, CA).
For insulin release, glucose (3 g͞kg of body weight) was injected i.p.; blood was collected by retroorbital eye bleed at 0, 2, 5, 15, and 30 min after the injection and immediately centrifuged, and the plasma was stored at Ϫ20°C. Insulin levels were measured by using a commercially available RIA kit (Linco, St. Louis, MO).
For the ITT, fasted male mice were injected with insulin (0.75 units͞kg of body weight, Sigma, St. Louis, MO), and blood glucose levels were measured before and at 15, 30, 60, and 90 min after insulin injection.
In separate experiments, mice were i.p. injected with saline or Ucn 2 peptide (0.1 mg͞kg of body weight) 20 min before the ITT and GTT or with astressin 2B (30 mg͞kg of body weight) 20 min before the GTT.
Hyperinsulinemic Euglycemic Clamp Studies. Animals. Male Ucn 2-null mice and age-matched WT littermates were studied at 16-18 weeks of age. They were placed on a standard lab chow diet or a high-fat diet (55% of calories from fat, diet TD 93075, Harlan Teklad, Indianapolis, IN) for 3 weeks and housed under controlled temperature (22 Ϯ 2°C) and lighting [12-h light (0700-1700) and 12-h dark (1700-0700)] conditions with free access to water and food. Clamp experiments. At least 6 days before the hyperinsulinemic euglycemic clamp experiments, an indwelling catheter was implanted into the left jugular vein of mice. All procedures were approved by the Yale University Animal Care and Use Committee.
After an overnight fast, [3-3 H]glucose (HPLC-purified; PerkinElmer, Boston, MA) was infused at a rate of 0.05 Ci͞min (1 Ci ϭ 37 GBq) for 2 h to assess the basal glucose turnover. After the basal period, a hyperinsulinemic euglycemic clamp was conducted for 120 min with a primed and continuous infusion of human insulin (105 pmol͞kg for the prime and 15 pmol͞kg͞min for the infusion) (Novo Nordisk, Princeton, NJ) to raise plasma insulin within the physiological range. Blood samples (10 l) were collected at 10-to 20-min intervals for the immediate measurement of plasma glucose, and 20% dextrose was infused at variable rates to maintain plasma glucose at basal concentrations (Ϸ6.7 mM). To estimate insulin-stimulated whole-body glucose fluxes, [3-3 H] glucose was infused at a rate of 0.1 Ci͞min throughout the clamps, and 2-deoxy-D-[1-14 C]glucose (PerkinElmer) was injected as a bolus after 75 min of clamping to estimate the rate of insulin-stimulated tissue glucose uptake as described in ref. 32 . Blood samples (10 l) for the measurement of plasma 3 H and 14 C activities were taken at the end of the basal period and during the last 45 min of the clamp. Additional blood samples were obtained for the measurement of plasma insulin and free fatty acid concentrations at the end of the basal and clamp time period. At the end of the clamp, mice were anesthetized with sodium pentobarbital, and tissues were taken for biochemical measurements within 3 min: three muscles (gastrocnemius, tibialis anterior, and quadriceps) from each hindlimb, epididymal fat, liver brown fat, and heart. Each tissue sample was quickly dissected, frozen immediately by using liquid N 2 -cooled aluminum blocks, and stored at Ϫ80°C for later analysis. A detailed description of the biochemical analysis and calculations of the hyperinsulinemic euglycemic clamp studies can be found in Supporting Materials and Methods.
Body Composition Analysis Using Dual-Energy X-Ray Absorptiometry (DXA). All DXA measurements were conducted by using the GE-Lunar PIXImus (General Electric, Madison, WI) as described and validated in ref. 28 . Previously frozen mice were thawed and allowed to reach room temperature before being scanned by using 5 . Ucn 2 effects on muscle glucose uptake are mediated putatively by inhibition of insulin signaling. (a-f ) Ucn 2 inhibits insulin-induced Akt and ERK1͞2 phosphorylation. Differentiated C2C12 myotubes or cultured skeletal muscle cells were preincubated with or without Ucn 2 peptide (0.1, 1, or 10 nM) for 1 h before insulin treatment (10 nM for 5 min). Cell lysates were resolved by using 4 -12% gradient polyacrylamide gels. Gels were electrophoretically transferred to membranes and probed with antibodies specific for the phospho proteins pAkt (Ser-473) or pERK1͞2. Stimulation of Akt or ERK activation was calculated by fold activation of the phosphorylated form normalized to total and compared with the nontreatment controls (b, d, and f ). Ucn 2 dose dependently inhibits the insulin-induced phosphorylation of Akt (a-d) and ERK1͞2 (e and f ). (g) The effect of Ucn 2 on [ 3 H]2-deoxy-Dglucose uptake in differentiated C2C12 myotubes. Cells were incubated for 2 h in low-glucose, serum-free medium and treated with Ucn 2 (0.1, 1, or 10 nM) or without Ucn 2 (control) for 30 min before insulin administration (10 nM). Glucose uptake was measured 5 min after exposure to [ 3 H]2-deoxy-D-glucose. Nonspecific uptake was measured by incubating muscle tissue with cytochalasin B, which binds to the glucose uptake transporter (GLUT) and inhibits glucose transport into the cell. Specific uptake was calculated by subtracting nonspecific glucose from total glucose.
